{
  "docId": "019de075-3cec-7700-94db-076a5ce30d84",
  "docSlug": "8c2d629a90974743be7d15f16a23e50f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 56,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a standard 2x2 grid for program summary and a simple timeline for catalysts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-3cec-7700-94db-076a5ce30d84/26",
  "deckHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84",
  "deckJsonHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84.json",
  "deckAnchorHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.4,
        "y": 0.77
      },
      "kind": "chart",
      "text": "Upcoming catalysts: 2Q2024 IND/CTN, YE2024 Human PK/PD",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c3b1383-6589-4b76-9f26-8f5d5b492c78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.28,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "image",
      "text": "Antibody diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "987f0f02-4f35-4ae8-8b3c-0656eaf3f8ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.28,
        "x": 0.36,
        "y": 0.235
      },
      "kind": "list",
      "text": "Preferred target in large market: Vedolizumab is the preferred biologic in UC with >$5B in annual sales",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f93bc41-3777-42fd-ace9-bc7bb9e1d725",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.28,
        "x": 0.66,
        "y": 0.465
      },
      "kind": "list",
      "text": "Promising early data: SPY001 observed to match vedolizumab's potency and selectivity and has ~2x half-life in NHPs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5509d82-be0c-47e2-a56e-1329072fe842",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.28,
        "x": 0.66,
        "y": 0.235
      },
      "kind": "list",
      "text": "Clinically validated pharmacology: SPY001 observed to maintain vedolizumab's epitope with similar potency",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbbc0aef-3b18-499a-afb8-4c2a92080599",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.28,
        "x": 0.36,
        "y": 0.465
      },
      "kind": "list",
      "text": "Designed for differentiation: Q8W+ dosing, faster time to onset, patient-friendly formulation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3ca2830-f600-43bd-a44b-38e1e9128429",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "SPY001 is a potentially best-in-class anti-α4β7 mAb with near-term de-risking studies anticipated",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e36a9f9-8626-4a3b-aba8-abf4a6eb4606",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Thesis archetype",
      "slug": "thesis-archetype",
      "agent": null,
      "layer": "slide",
      "matchId": "daae947d-1004-4fcf-96ed-ca8adc2f7c2f",
      "evidence": "list/bullet: Promising early data: SPY001 observed to match vedolizumab's potency and selectivity and has ~2x half-life in NHPs",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "0783aa15-4946-4614-96c8-6e4e421a85e2",
      "evidence": "Upcoming catalysts section uses a linear timeline representation",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 30,
      "from": 13,
      "beatId": "5fcb9464-3068-4031-9434-ce301bbe9fd3",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents the company's solution, including its pipeline and strategy",
      "position": 3,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 13,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "1d2b0809-4269-4aea-a725-b67c9452d570",
      "evidence": "The document presents the company's solution, including its pipeline and strategy",
      "position": 2,
      "objective": "What is the company's solution?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.8,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}